is a scattergram of the venous-arteriolar ratio in the study based on mean vessel width. From this it can be seen that the variation is very large. The mean was 1-33: 1 or 2-66: 2. This is very much less than the venous-arteriolar ratio of 4: 2 which is widely quoted in diabetic retinopathy, and varies little from the accepted 3: 2 ratio in the normal population. Fig 5 is a distribution curve based again on the venous-arteriolar ratios and it is interesting to note that the distribution appears to be binomial with perhaps a slight skew to the right. There would therefore appear to be little difference in the venous-arteriolar ratios between this diabetic population and that which one would expect in a normal population. Another question worth considering was whether or not there was any association between the duration of the disease and the venous calibre. Unfortunately, such detail was not always available and it was possible to obtain reasonably accurate information on only 51 persons. In this study no real association between the years affected and venous diameter was noted and there was no obvious difference in the mean venous calibre between thejuvenile insulin-dependent diabetics of whatever standing and the mature, generally insulin-independent, diabetics. There would therefore appear to be no difference between the venous diameters of young juvenile diabetics and old mature diabetics, certainly on the basis of this small, highly selected population. Similarly, in this study the venous-arteriolar ratio would appear to differ but little from that which one would expect to find in a normal population. This, of course, appears to differ considerably from previous observations. The study itself can be criticized on a number of counts, the most important being that of the selection of the population. A normal population has not been similarly studied as yet and no interor intraobserver studies have been carried out. It is none the less surprising that obvious differences did not occur between the young and old diabetics and that the venous-arteriolar ratio differed little from that expected in a normal population. Four aspects of systemic corticosteroid and corticotrophic hormone therapy are discussed: steroid (posterior subcapsular) cataracts, steroid glaucoma, serous exudates and sudden withdrawal phenomena. The first three have all been reported before (Black et al. 1960 , Crews 1963 , Alfano 1963 , Jain & Kapalmit 1966 , Williamson & Dalakos 1967 , Williamson et al. 1969 ) but the last does not appear to have been documented.
A group of 356 patients studied in the Centre for Rheumatic Diseases and the University Eye Department, Western Infirmary, Glasgow, was recorded by Williamson et al. (1969) . However, a new look at these patients brings out some interesting features. Twenty per cent of patients treated with over 15 mg prednisolone per day or its equivalent for between two and eight years will develop steroid cataracts. Only 5% of patients who receive less than 15 mg per day will develop posterior subcapsular opacities. Once developed, the opacities progress slowly and it is quite safe to continue with the same dosage of steroid until the opacities reach Grade III (Crews 1963) . Beyond this level, increasing difficulty with vision will result and once the opacities are Grade IV, extending into the cortex, the likelihood is that they will progress relentlessly despite cessation of steroid therapy. Systemic steroid glaucoma is extremely rare.
Macular exudates are described in three patients; two were receiving adrenocorticotrophic hormone (Acthar Gel) 20 i.u. per day intramuscularly for over two years, and one was receiving excessive doses of depot tetracosactrin (Synacthen Depot) as a result of a misunderstan-ding, for only six weeks. The exact relationship between therapy and the exudates cannot be determined at present but a dramatic and prolonged remission in ocular signs followed reduction in the dosage of corticotrophin.
Finally, 6 rheumatoid arthritic patients developed acutely red eyes, clinically a nonspecific conjunctivitis, after sudden withdrawal ofsystemic steroid therapy. None of them had any history of eye disease and all had been examined prior to these episodes. Biopsy of one patient's conjuctiva revealed a nonspecific chronic round cell infiltrate with no predominance of eosinophils. Release from the suppressing effect of steroid therapy seems to be the most plausible explanation. AJl the red eyes resolved in a few days without treatment.
Quantitative Assessment of Colour Vision in Tobacco Amblyopia [Summary] by I A Chisholm FRCSEd (Tennent Institute ofOphthalmology, University ofGlasgow, Western Infirmary, Glasgow WI) One ofthe diagnostic criteria of tobacco amblyopia is the finding of an acquired colour defect. The Farnsworth Munsell 100 Hue test was found to be the most useful means of analysing the colour defect in these patients, prior to and whilst on treatment. The patient's error score for the test can be calculated and expressed numerically or graphically. In a group of 65 patients whose mean age was 67 years, suffering from untreated tobacco amblyopia, the mean error score for the Farnsworth Munsell 100 Hue test was 732 ± 236. Apart from 5 of the patients, all received parenteral vitamin B12 therapy. Initially, they were given either cyanocobalamin or hydroxocobalamin and, as previously reported by Chisholm et al. (1967) , the improvement in colour vision, indicated by a falling 100 Hue error score, was greater with hydroxocobalamin than cyanocobalamin. All patients were subsequently transferred to hydro-xocobalamin therapy at a dose of 1,000 ,g daily for the first 14 days and then thrice weekly. Adjustments were made dependent on the patient's response. The patients were advised that it was not necessary to alter their smoking habits. Improvement in colour discrimination may be observed by studying the change in the 100 Hue profile or in the numerical error score. With time there is a noticeable shrinkage of the area of error in profile. Patients with tobacco amblyopia were found to improve when given hydroxocobalamin even when continuing to smoke and their rate of recovery was as good as that obtained when the tobacco habit was given up. Patients with addisonian pernicious anxmia with field defects, and who smoke, improve more slowly than patients with tobacco ambylopia in which diabetes is present. Speakers for the motion were Mr Dermot Pierse and Mr John Dobree; against the motion, Mr Eric Arnott and Mr Peter Blaxter.
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